Experimental study of dendrimer-based nanoparticles with RGD-peptide for anticancer radionuclide therapyстатья
Информация о цитировании статьи получена из
Web of Science ,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 16 марта 2022 г.
Авторы:
Stukalov Yu V. ,
Grigorieva E.Yu ,
Smirnova A.V. ,
Lipengolts A.A. ,
Kubasova I.Yu ,
Pozdniakova N.V. ,
Lukashina M.I.
Журнал:
Bulletin of RSMU
Том:
7
Номер:
6
Год издания:
2018
Издательство:
Pirogov Russian National Research Medical University
Местоположение издательства:
Moscow
Первая страница:
113
Последняя страница:
119
DOI:
10.24075/brsmu.2018.089
Аннотация:
Radionuclide therapy (RNT) is an effective modality for treating multiple metastases in patients with cancer. The list of malignancies that can be managed with RNT expands with the arrival of novel tumoritropic radiopharmaceuticals (RP). A versatile delivery platform capable of carrying various therapeutic and diagnostic radionuclides, as well as vector molecules needed to achieve sufficient specificity to tumor cells and ensure therapeutic efficacy may hold great promise for radiation therapy. The aim of this work was to assess the performance of a delivery system based on the original dendrimer. The dendrimer demonstrated low toxicity in mice (LD 50 was 779 ± 111 mg/kg). To study the specificity of the dendrimer to tumor cells and its therapeutic efficacy, we used a nanoplatform (NP) composed of the dendrimer itself, the RGD peptide and 188 Re ( 188 Re-NP). Lewis lung carcinoma LLC1 was used as a tumor model. The biodistribution analysis revealed that the compound effectively accumulated in the tumor demonstrating a tumor-to-normal ratio >1 (relative to healthy organs and tissues) and retention time of at least 6 hours. Injections of 185 MBq/kg 188 Re-NP caused a statistically significant inhibition of tumor growth (p < 0.05) by day 7 following the injection (Т/С = 5%), which remained stable for 6 days. Our findings suggest that the proposed dendrimer is a promising platform for RP delivery. © 2018 Pirogov Russian National Research Medical University. All rights reserved.
Добавил в систему:
Липенгольц Алексей Андреевич